Fig. 4
From: Repurposing nitric oxide donating drugs in cancer therapy through immune modulation
CD8+ T cells are essential for the repression of tumor growth mediated by low-dose SNAP. (A) Tumor tissues were isolated from LL2 tumor-bearing mice after SNAP treatment (left), and the tumor sizes (middle) and the tumor weights (right) were analyzed on the 20th day. (B) Tumor tissues were isolated from LL2 tumor-bearing mice after ISMN treatment (left), and the tumor sizes (middle) and the tumor weights (right) were analyzed on the 20th day. (C) FACS analysis of intratumoral CD8+ T cells between the control group and low-dose SNAP treatment group. (D) FACS analysis of intratumoral CD8+ T cells between the control group and the low-dose ISMN treatment group. The mice were sacrificed, and tumor-infiltrating lymphocytes were analyzed on the 20th day after implantation of LL2 tumor cells. (E) Violin plot revealing Ccr7 expression levels in dendritic cells. Each dot represents one cell. (F) Flow cytometry analysis of intratumoral mature dendritic cells between the control group and low-dose SNAP treatment group. (G) Schematic of CD8+ T-cell depletion in mice (upper). Representative histogram of CD8+ expression on splenocytes (lower). (H) Simplified diagram of CD8+ T-cell depletion in the LL2 tumor-bearing mice (upper). LL2 tumor-bearing mice were treated with low-dose SNAP (0.004 mg/kg) and anti-CD8 antibody (200 μg/time) (lower). Anti-IgG antibody was used as the control. Both antibodies and SNAP were administered via intraperitoneal injection. The column scatter dot plot represents the mean values ± SEMs. *p < 0.05, **p < 0.01, versus the control group. P-values of the tumor results and violin plots were obtained by two-way ANOVA and the Wilcox test, ***p < 0.001, ns, no significant difference. The tumor volumes were measured every 2 days beginning on the 10th day after tumor implantation